Moreover, the application of a targeted FFA4 agonist resulted in substantial alleviation of IMQ-triggered psoriasis-like skin aberrations and inhibited the transition of CD4+ T cells into Th17 cells (43). This evidence concerns the gene CD4 and psoriasis.